One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Despite what you’ve read, there is no established diet for lupus. There are certain foods that may improve life while living with lupus, and that are certain foods that can worsen your flares and how ...

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, ...

Brepocitinib, an investigational oral therapy, failed to show any benefits beyond a placebo in a Phase 2 clinical trial that tested it in adults with moderate to severely active systemic lupus ...

Everyone who lives with lupus will experience the disease differently. The symptoms vary and not all people will suffer from the same ones. Remission — the time when lupus isn’t active — also varies ...

Ventus Therapeutics plans to develop a new treatment candidate for lupus and other inflammatory diseases marked by the activation of the type 1 interferon immune system pathway, the company recently ...

As we flip the page to a new year, the pull of hustle culture on social media hasn’t seemed to change. Messages urge us to do more, achieve more, and push harder. But for those of us living with lupus ...

Part of living with lupus is knowing that your body lives outside of the norm. It means accepting that, for the most part, you have no predictable sleeping pattern, and if you should be lucky enough ...

When the protein TLR7, or toll-like receptor 7 — which normally triggers an immune response against viruses and bacteria — instead builds up in immune cells, the immune system may turn against its own ...

Galapagos officially has launched a Phase 2 clinical trial that will test its oral therapy GLPG3667 — designed to ease disease severity in people with systemic lupus erythematosus (SLE) — at a half ...

Excessive production of type I interferon (IFN-I) — a molecule that mediates immune and inflammatory responses — in people with systemic lupus erythematosus (SLE) may be caused by small fragments of ...